Development and Validation of a Simplified Prognostic Score in SCLC

Elodie Negre; Amandine Coffy; Alexandra Langlais; Jean-Pierre Daures; Armelle Lavole; Elisabeth Quoix; Olivier Molinier; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Virginie Westeel; Franck Morin; Benoît Roch; Jean-Louis Pujol

doi:10.1016/j.jtocrr.2020.100016

Development and Validation of a Simplified Prognostic Score in SCLC

JTO Clin Res Rep. 2020 Feb 12;1(1):100016. doi: 10.1016/j.jtocrr.2020.100016. eCollection 2020 Mar.

Authors

Affiliations

¹ Department of Thoracic Oncology, Montpellier Regional University Hospital, Montpellier, France.
² Laboratory of Biostatistics and Epidemiology, University Institute for Clinical Research, Montpellier University, Montpellier, France.
³ French Cooperative Thoracic Intergroup (IFCT), Paris, France.
⁴ Department of Pneumology, Hôpital Tenon, Paris, France.
⁵ Department of Pneumology, University Hospital, Strasbourg, France.
⁶ Department of Pneumology, Centre Hospitalier Le Mans, Le Mans, France.
⁷ Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
⁸ Department of Thoracic Oncology, CHITS CH Sainte Musse, Toulon, France.
⁹ Thoracic Oncology Unit, CHU Grenoble Alpes, Grenoble, France.
¹⁰ Department of pneumology, Hopital Universitaire, Besançon, France.
¹¹ Montpellier Cancer Research Institute, INSERM U1194, Montpellier, France.

Abstract

Introduction: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their overall survival (OS).

Methods: The SPS was developed exploring the Montpellier University Hospital retrospective database of 401 patients over a 16-year period. All patients had received etoposide - platinum-based chemotherapy as first-line treatment. The SPS development took into account significant determinants of OS in the Cox model, weighted by their regression β coefficients. Validation of the consequent SPS has been done separately in a combined population of 213 patients accrued from two different published trials (NCT03059667 and NCT00930891).

Results: The significant independent determinants of OS included the following: (1) American Joint Committee on Cancer TNM stage IV (hazard ratio [HR]: 2.52; 95% confidence interval [CI]: 1.91-3.33); (2) Eastern Cooperative Oncology Group performance status greater than 1 (HR: 2.27; 95% CI: 1.79-2.87); (3) the presence of liver metastases (HR: 1.66; 95% CI: 1.29-2.15); and (4) neutrophil-to-lymphocyte ratio greater than 4 (HR: 1.39; 95% CI: 1.11-1.92). The SPS generated with these four variables, segregated three groups (good, intermediate, and poor prognosis) with respective median OS of 26.9 months (95% CI: 20.1-38.9), 11.5 months (95% CI: 9.8-13.0), and 6.8 months (95% CI: 5.8-8.3; log-rank p < 10^-4). Harrell's C statistic estimate was 0.68 ± 0.012, suggesting goodness of calibration. In the validation cohort, the SPS segregated the aforementioned three subgroups in a nearly similar manner, with respective median OS: 27.2, 12.3, and 8.6 months (log-rank p < 10^-3; Harrell's C statistic: 0.58 ± 0.02).

Conclusions: The SPS is easy to calculate in real-life practice and efficiently discriminates three populations with different prognoses. This study deserves further validation of this score in patients with SCLC receiving immunochemotherapy.

Keywords: Chemotherapy; Prognosis; Prognostic score; Serum markers; Small cell lung cancer.

Associated data

ClinicalTrials.gov/NCT03059667
ClinicalTrials.gov/NCT00930891